Regenxbio (RGNX) EBITDA Margin (2015 - 2025)
Regenxbio (RGNX) reported EBITDA Margin of -177.23% for Q4 2025, up 45.95 percentage points from -223.18% a year earlier but down 14.03 percentage points from the prior quarter.
Powered by 
Analysis
Regenxbio (RGNX) EBITDA Margin (2015 - 2025) Analysis & Trends
For FY2025, Regenxbio posted EBITDA Margin of -85.42%, up 175.16 percentage points from FY2024.
- EBITDA Margin has a five-year change of -13.71 percentage points (FY2020 to FY2025).
- By year, EBITDA Margin came in at -260.57% in FY2024 (+17.35 pp), -277.93% in FY2023 (-56.18 pp), -221.75% in FY2022 (-257.81 pp) and 36.05% in FY2021 (+107.76 pp).
- Five-year quarterly EBITDA Margin spans a low of -382.04% in Q1 2024 and a high of 79.33% in Q4 2021.
- Year over year, EBITDA Margin gained in five of the last eight quarters, with an average year-over-year change of +68.12 percentage points.
- The high point for year-over-year EBITDA Margin in five years was Q1 2025 (a gain of 400.11 percentage points); the low point was Q4 2022 (a drop of 250.47 percentage points).
- Per Business Quant data, the three quarters before Q4 2025 came in at -163.20% (Q3 2025), -277.98% (Q2 2025) and 18.07% (Q1 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Regenxbio | 404.61 Mn | -528.48 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -177.23% |
| Sep 30, 2025 | -163.20% |
| Jun 30, 2025 | -277.98% |
| Mar 31, 2025 | 18.07% |
| Dec 31, 2024 | -223.18% |
| Sep 30, 2024 | -240.18% |
| Jun 30, 2024 | -233.17% |
| Mar 31, 2024 | -382.04% |
| Dec 31, 2023 | -268.17% |
| Sep 30, 2023 | -209.55% |
| Jun 30, 2023 | -343.76% |
| Mar 31, 2023 | -323.85% |
| Dec 31, 2022 | -171.14% |
| Sep 30, 2022 | -254.59% |
| Jun 30, 2022 | -183.44% |
| Mar 31, 2022 | -310.27% |
| Dec 31, 2021 | 79.33% |
| Sep 30, 2021 | -177.17% |
| Jun 30, 2021 | -227.03% |
| Mar 31, 2021 | -223.01% |
API Access
Regenxbio EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=RGNX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "RGNX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=RGNX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();